Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis

Sumona Bhattacharya; Gianna Stoleru; Preet Patel; Ameer Abutaleb; Kristen Stashek; Raymond K Cross

doi:10.1093/ibd/izab254

Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis

Inflamm Bowel Dis. 2022 May 4;28(5):811-814. doi: 10.1093/ibd/izab254.

Authors

Sumona Bhattacharya^{1

2}, Gianna Stoleru³, Preet Patel³, Ameer Abutaleb², Kristen Stashek⁴, Raymond K Cross²

Affiliations

¹ Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
² University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, USA.
³ University of Maryland Medical Center, Department of Medicine, Baltimore, MD, USA.
⁴ University of Maryland School of Medicine, Department of Pathology, Baltimore, MD, USA.

No abstract available

Keywords: mycophenolate mofetil; mycophenolate mofetil colitis; mycophenolate mofetil gastrointestinal toxicity.

Plain language summary

Authors performed a chart review to identify cases of mycophenolate mofetil gastrointestinal toxicity at our institution. In this cohort, friability was associated with severe disease; and nausea and erythema were associated with poor prognosis.

MeSH terms

Gastrointestinal Diseases* / chemically induced
Humans
Immunosuppressive Agents / adverse effects
Mycophenolic Acid* / adverse effects
Prognosis
Risk Factors

Substances

Immunosuppressive Agents
Mycophenolic Acid